BioTwin equips primary care and frontline clinics with biomarker-driven risk detection across five clinical domains and fifteen health conditions, from a simple at-home collection protocol.
BioTwin is positioned as a clinical decision support tool (CDST). BioTwin augments clinical judgment with AI-driven insights from biomarker analysis. BioTwin does not replace the physician.
BioTwin is designed to augment clinical judgment. All flagged risk signals are routed to the treating physician for review, validation, and follow-up action.
Clinical authority remains fully with the physician. BioTwin provides structured risk summaries and longitudinal monitoring signals to support clinical triage and follow-up decisions.
BioTwin's models are grounded in peer-reviewed biomarker research and established clinical literature, with validation underway in clinical pilots.
The BioTwin 5-10-15 Protocol aims to deliver a comprehensive biological scan of you, powered by your personal virtual twin. It combines multi-omic analysis (genomic, proteomic, metabolomic biomarkers), clinical and lifestyle assessments, and continuous data from wearables, apps, imaging, and medical records, alongside facial, skin, voice, and movement biomarkers. All signals aim to be unified into a continuously updated virtual twin, providing a 360-degree view of your health and how it evolves over time, not a one-time snapshot. 5 days. 10 drops. 15 health conditions.
Simple & effortless samples collection over 5 days, flexible to fit your schedule and capture biological variability.
Low-friction at-home collection using finger blood, urine, and saliva. No clinic visit required.
One unified view across five clinical domains: Oncology, Neurology, Cardiology, Lifestyle, and Life & Health Span.
5 clinical domains. 15 health conditions.
BioTwin protocol aims to monitor biological signals, screen for meaningful deviations from each individual's baseline, and flag risk supporting clinical, triage and routing decisions. BioTwin does not replace physicians. BioTwin aims to provide a longitudinal decision-support research layer that strengthens primary-care workflows and reduces uncertainty, latency and diagnostic burden.
Flags early biological risk signals to support imaging and referral prioritization.
Multi-Cancer Early Detection (MCED)Helps flag early biological risk, including where no screening exists
Helps refine imaging, biopsy, and referral prioritization
Helps support surveillance and recurrence monitoring decisions
Supports earlier specialist triage before overt symptoms appear.
Helps identify early biological risk before overt symptoms
Helps support specialist referral and diagnostic triage pathways
Helps monitor progression and treatment response longitudinally
Highlights elevated cardiac risk for faster follow-up and intervention planning.
Helps flag elevated risk before acute events or decompensation
Helps support referral, imaging, and therapy optimization decisions
Helps monitor biological response to treatment over time
Tracks hidden metabolic decline and personalizes lifestyle action.
Track hidden metabolic and performance decline early
Personalize intervention intensity before complications emerge
Track whether lifestyle and therapy changes actually work
Transforms biological drift into proactive healthspan decisions.
Extends healthspan through continuous trajectory optimization
Detects early multi-system decline before disease onset
Converts biological drift into proactive healthspan action
Clinical decision-support research tool — not a diagnostic replacement. Currently in validation phase.
BioTwin serves hospitals, clinics, and their patients across multiple clinical workflows.
Multi-domain risk stratification across oncology, neurology, cardiology, lifestyle medicine, and life & health span, supported by low-friction at-home sample collection.
Track patient trajectories over time using repeat measurements, trend analysis, and longitudinal drift detection across monitored clinical areas.
Risk-stratify patient populations, identify individuals requiring closer follow-up, and support more efficient resource allocation.
Healthspan and wellbeing optimization programs built on longitudinal multi-system monitoring and personalized trajectory tracking.
| BioTwin | One-off Tests | Wellness Platforms | |
|---|---|---|---|
| Approach | Longitudinal virtual twin modeling | Single snapshot testing | Periodic biomarker panels |
| Scope | Multi-domain health conditions | Single condition focus | General wellness metrics |
| Clinical integration | Clinician-integrated decision support | Standalone result delivery | Coaching only |
| Output | Structured routing logic | Signal detection only | Descriptive reports |
A structured pathway from initial scoping to evaluation. Pilot cohorts typically range from 50 to 500 patients, run over 6 to 18 months, and include joint IRB review, data governance agreements, and shared validation reporting.
Define clinical or research objectives and assess alignment with BioTwin capabilities.
Define pilot cohort size, inclusion criteria, and measurable success metrics.
Joint IRB review, data-sharing agreements, and informed consent framework.
At-home collection logistics, clinician dashboard onboarding, and longitudinal follow-up.
Outcome review, validation reporting, and pathway to expanded deployment.
All BioTwin clinical research adheres to established ethical and regulatory standards. IRB approval, informed consent, and formal data governance agreements are required for all collaborations. Patient privacy, auditability, and data security are foundational. BioTwin is positioned as a clinical decision support tool under applicable regulatory frameworks; commercial deployment is planned for 2027.
Three pathways for healthcare providers, hospital networks, and research institutions.
Run BioTwin in your clinic as part of a research collaboration. Joint IRB review, longitudinal cohort follow-up, and shared validation reporting.
Request a pilot →Joint research projects with the BioTwin scientific team. Academic partnerships, sponsored studies, and federated data collaborations.
Explore partnerships →Express interest in the commercial deployment planned for 2027. Limited onboarding slots for primary-care partners and hospital networks.
Register interest →For patients looking to start their personal journey, see TwinMe.